154 related articles for article (PubMed ID: 12731520)
21. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications.
Kang EM; Tisdale JF
Curr Hematol Rep; 2004 Jul; 3(4):274-81. PubMed ID: 15217557
[TBL] [Abstract][Full Text] [Related]
22. Gene therapy rising?
Hoag H
Nature; 2005 May; 435(7041):530-1. PubMed ID: 15917820
[No Abstract] [Full Text] [Related]
23. US authorities uphold suspension of SCID gene therapy.
Fox JL
Nat Biotechnol; 2003 Mar; 21(3):217. PubMed ID: 12610555
[No Abstract] [Full Text] [Related]
24. Gene therapy. Panel urges limits on X-SCID trials.
Kaiser J
Science; 2005 Mar; 307(5715):1544-5. PubMed ID: 15761128
[No Abstract] [Full Text] [Related]
25. Gene therapists hopeful as trials resume with childhood disease.
Check E
Nature; 2004 Jun; 429(6992):587. PubMed ID: 15190314
[No Abstract] [Full Text] [Related]
26. Occurrence of leukaemia following gene therapy of X-linked SCID.
Kohn DB; Sadelain M; Glorioso JC
Nat Rev Cancer; 2003 Jul; 3(7):477-88. PubMed ID: 12835668
[TBL] [Abstract][Full Text] [Related]
27. [Setback for gene therapy: Two cases of leukemia in a French trial].
Richter J; Relander T; Fasth A; Karlsson S
Lakartidningen; 2003 Feb; 100(7):498-500. PubMed ID: 12640983
[No Abstract] [Full Text] [Related]
28. Harmful potential of viral vectors fuels doubts over gene therapy.
Check E
Nature; 2003 Jun; 423(6940):573-4. PubMed ID: 12789298
[No Abstract] [Full Text] [Related]
29. Gene therapy resumes.
Novak K
Nat Rev Cancer; 2002 Nov; 2(11):813. PubMed ID: 12442759
[No Abstract] [Full Text] [Related]
30. Gene therapy. As Gelsinger case ends, gene therapy suffers another blow.
Couzin J; Kaiser J
Science; 2005 Feb; 307(5712):1028. PubMed ID: 15718439
[No Abstract] [Full Text] [Related]
31. Medicine. Gene therapy--new challenges ahead.
Williams DA; Baum C
Science; 2003 Oct; 302(5644):400-1. PubMed ID: 14563994
[TBL] [Abstract][Full Text] [Related]
32. Good news for gene therapy.
Berns A
N Engl J Med; 2004 Apr; 350(16):1679-80. PubMed ID: 15084702
[No Abstract] [Full Text] [Related]
33. Too high a cost for a cure?
Boyce N
US News World Rep; 2002 Oct; 133(14):34. PubMed ID: 12389521
[No Abstract] [Full Text] [Related]
34. Gene therapy put on hold as third child develops cancer.
Check E
Nature; 2005 Feb; 433(7026):561. PubMed ID: 15703711
[No Abstract] [Full Text] [Related]
35. Retroviral vectors: new applications for an old tool.
Barquinero J; Eixarch H; Pérez-Melgosa M
Gene Ther; 2004 Oct; 11 Suppl 1():S3-9. PubMed ID: 15454951
[TBL] [Abstract][Full Text] [Related]
36. [Methodology of gene therapy: adverse events and further technological developments].
Hamada H
Nihon Rinsho; 2010 Aug; 68 Suppl 8():601-6. PubMed ID: 20979308
[No Abstract] [Full Text] [Related]
37. Is retroviral gene marking too dangerous to use?
Brenner MK; Heslop HE
Cytotherapy; 2003; 5(3):190-3. PubMed ID: 12850996
[No Abstract] [Full Text] [Related]
38. Therapy on trial.
Hughes V
Nat Med; 2007 Sep; 13(9):1008-9. PubMed ID: 17828211
[No Abstract] [Full Text] [Related]
39. Gene therapy: X-SCID transgene leukaemogenicity.
Thrasher AJ; Gaspar HB; Baum C; Modlich U; Schambach A; Candotti F; Otsu M; Sorrentino B; Scobie L; Cameron E; Blyth K; Neil J; Abina SH; Cavazzana-Calvo M; Fischer A
Nature; 2006 Sep; 443(7109):E5-6; discussion E6-7. PubMed ID: 16988659
[TBL] [Abstract][Full Text] [Related]
40. Gene therapy insertional mutagenesis insights.
Davé UP; Jenkins NA; Copeland NG
Science; 2004 Jan; 303(5656):333. PubMed ID: 14726584
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
